Summary
Inspiratory Muscle Training is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 1 registered trial linking Inspiratory Muscle Training to ME/CFS: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2022. The literature layer holds 6 publications for this pair: 6 PubMed search records. Publication years run from 2023 to 2026. Items here are search-derived or curated references rather than classified trial reports; treat them as leads to read, not as graded evidence.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 191 candidate agents are logged for ME/CFS, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 13.5 (trials 2.5, literature 6.0, tier 5, approved bonus 0.0) |
| Registered trials | 1 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 0 other |
| Linked publications | 6 (6 PubMed search records) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Not recorded |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT05196529 | Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors York University · 2022 | completed | Not applicable | 40 |
Published literature
- PubMed record (biomarker-intervention search) Effects of physical rehabilitation interventions on pulmonary hypertension: an overview of systematic reviews of randomized controlled trials.Expert review of respiratory medicine · 2026 · PMID 42138156
- PubMed record (biomarker-intervention search) Effects of Cardiopulmonary Rehabilitation on Cardiorespiratory Fitness and Clinical Symptom Burden in Long COVID: Results From the COVID-Rehab Randomized Controlled Trial.American journal of physical medicine & rehabilitation · 2025 · PMID 38917451
- PubMed record (biomarker-intervention search) Effect of inspiratory muscle training on pulmonary function, respiratory muscle strength, aerobic performance, sports skills, and quality of life in wheelchair rugby athletes.Journal of bodywork and movement therapies · 2024 · PMID 39593611
- PubMed record (biomarker-intervention search) Pulmonary Rehabilitation Associated with Noninvasive Ventilation on Physical Capacity and Quality of Life in Post-COVID-19: A Randomized Controlled Double-Blinded Clinical Trial Protocol.Journal of multidisciplinary healthcare · 2024 · PMID 38596000
- PubMed record (biomarker-intervention search) The effects of inspiratory muscle training on cardiorespiratory functions in juvenile idiopathic arthritis: A randomized controlled trial.Pediatric pulmonology · 2024 · PMID 38038160
- PubMed record (biomarker-intervention search) Clinical aspects and targeted inspiratory muscle training in children and adolescents with Fontan circulation: a randomized controlled trial.Cardiovascular diagnosis and therapy · 2023 · PMID 36864956
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
Clinical notes: Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Inspiratory Muscle Training approved for ME/CFS?
Inspiratory Muscle Training is tracked by OSMF as an investigational option for ME/CFS; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Inspiratory Muscle Training in clinical trials for ME/CFS?
ClinicalTrials.gov lists 1 registered trial linking Inspiratory Muscle Training to ME/CFS: 1 has completed. None of the registered studies carries a drug-development phase label, which is typical for behavioural, device and supplement protocols. It plans or enrolled 40 participants. Registered activity dates to 2022.
What does the evidence show for Inspiratory Muscle Training in ME/CFS?
Inspiratory Muscle Training has 1 completed trial and 6 linked publications for ME/CFS. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.